SCHEMBL5723730

SCHEMBL5723730

CSc1ccc(-c2cc3c(cc2C(O)c2cc(F)cc(F)c2)OCO3)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.39
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
P4HB P07237 4/20 0.35
CYP19A1 P11511 1/20 0.35
PTGS1 P23219 2/20 0.34
SMAD3 P84022 1/20 0.33
GAA P10253 2/20 0.32
MAPT P10636 2/20 0.32
CLK1 P49759 1/20 0.32
DYRK1A Q13627 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
HPGD P15428 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
EDNRA P25101 1/20 0.32
GCGR P47871 2/20 0.31
MAPK14 Q16539 2/20 0.31
TP53 P04637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5723821 0.90 PTGS2 (0.41) PTGS2MEN1KMT2AP4HBCYP19A1
SCHEMBL5723125 0.85 EDNRA (0.39) PTGS2MEN1KMT2AP4HBPTGS1
SCHEMBL5723608 0.82 PTGS2 (0.36) PTGS2MEN1KMT2APTGS1GAA
SCHEMBL5723347 0.81 GAA (0.36) PTGS2MEN1KMT2APTGS1GAA
SCHEMBL5723365 0.81 PTGS2 (0.64) PTGS2PTGS1
SCHEMBL5723681 0.81 PTGS2 (0.34) PTGS2MEN1KMT2AP4HBCYP19A1
SCHEMBL6139744 0.80 GAA (0.41) MEN1KMT2ACYP19A1GAAMAPT
SCHEMBL6139589 0.79 CYP1A2 (0.39) KMT2AP4HBCYP19A1SMAD3MAPT
SCHEMBL6724471 0.78 PTGS2 (0.60) PTGS2MEN1KMT2APTGS1MAPT
SCHEMBL6139079 0.74 EDNRA (0.36) PTGS2MEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1406609-B1 SUBSTITUTED ARYL COMPOUNDS AS NOVEL CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2006-09-06 EP disclosed
US-20050059665-A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2005-03-17 US disclosed
US-6825185-B2 IMPROVING THE CARDIOVASCULAR PROFILE OF A COX-2 SELECTIVE INHIBITOR BY ADMINISTERING WITH 3-HYDROXY-3- METHYLGLUTARYL COENZYME A, AN ANTIPLATELET AGENT, A THROMBIN INHIBITOR OR A THROMBOXANE INHIBITOR NITROMED, INC. 2004-11-30 US disclosed
US-20040116431-A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2004-06-17 US disclosed
US-6706724-B2 ANTITUMOR AGENTS; ANTIINFLAMMATORY AGENTS; ANALGESICS; ANTIPYRETIC AGENT NITROMED, INC. 2004-03-16 US disclosed
US-20020119977-A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use related applications NICOX S.A. (FR) 2002-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059665-A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGES, PTGER4, PTGS1 PTGS2 4/4885MEN1 4538/4885KMT2A 2598/4885
US-20020119977-A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use related applications PTGS2, PTGES2, PTGES PTGS2 1/4885MEN1 4707/4885KMT2A 2711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.